Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Voltalia SA: Voltalia wins a 30-year concession for the largest solar plant in West Balkans
Voltalia SA: Voltalia wins a 30-year concession for the largest solar plant in West Balkans
Voltalia SA: Voltalia wins a 30-year concession for the largest solar plant in West Balkans
eqs_en 
0 28.05.20
DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax publishes universal registration document 2020 'Document d'Enregistrement Universel'
eqs_en 
0 25.05.20
DGAP-News: Abivax veröffentlicht Referenzdokument 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax veröffentlicht Referenzdokument 2020 'Document d'Enregistrement Universel'
DGAP-News: Abivax veröffentlicht Referenzdokument 2020 'Document d'Enregistrement Universel'
eqs_de 
0 25.05.20
DGAP-News: Abivax erhält Genehmigung der deutschen Arzneimittelzulassungsbehörde für klinische ABX464 Phase-2b/3-COVID-19-Studie
DGAP-News: Abivax erhält Genehmigung der deutschen Arzneimittelzulassungsbehörde für klinische ABX464 Phase-2b/3-COVID-19-Studie
DGAP-News: Abivax erhält Genehmigung der deutschen Arzneimittelzulassungsbehörde für klinische ABX464 Phase-2b/3-COVID-19-Studie
eqs_de 
0 25.05.20
DGAP-News: Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
DGAP-News: Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
DGAP-News: Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
eqs_en 
0 25.05.20
RUBIS: Results from the capital increase reserved for Group employees
RUBIS: Results from the capital increase reserved for Group employees
RUBIS: Results from the capital increase reserved for Group employees
eqs_en 
0 22.05.20
ALD: Update on the share buyback program
ALD: Update on the share buyback program
ALD: Update on the share buyback program
eqs_en 
0 21.05.20
DGAP-News: Abivax verschiebt seine ordentliche Hauptversammlung auf den 19. Juni 2020
DGAP-News: Abivax verschiebt seine ordentliche Hauptversammlung auf den 19. Juni 2020
DGAP-News: Abivax verschiebt seine ordentliche Hauptversammlung auf den 19. Juni 2020
eqs_de 
0 20.05.20
DGAP-News: Abivax postpones its Annual General Meeting to June 19, 2020
DGAP-News: Abivax postpones its Annual General Meeting to June 19, 2020
DGAP-News: Abivax postpones its Annual General Meeting to June 19, 2020
eqs_en 
0 20.05.20
Showroomprive.com: Availability of shareholders' meeting documents
Showroomprive.com: Availability of shareholders' meeting documents
Showroomprive.com: Availability of shareholders' meeting documents
eqs_en 
0 18.05.20
DGAP-News: ABIVAX: €36 millionen nicht-verwässernde Finanzierung von Bpifrance für Abivax' ABX464 Covid-19-Programm
DGAP-News: ABIVAX: €36 millionen nicht-verwässernde Finanzierung von Bpifrance für Abivax' ABX464 Covid-19-Programm
DGAP-News: ABIVAX: €36 millionen nicht-verwässernde Finanzierung von Bpifrance für Abivax' ABX464 Covid-19-Programm
eqs_de 
0 15.05.20
DGAP-News: ABIVAX: €36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covid-19 program
DGAP-News: ABIVAX: €36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covid-19 program
DGAP-News: ABIVAX: €36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covid-19 program
eqs_en 
0 15.05.20
Pharnext Presents a Business Update Webcast on May 20th, 2020
Pharnext Presents a Business Update Webcast on May 20th, 2020
Pharnext Presents a Business Update Webcast on May 20th, 2020
eqs_en 
0 14.05.20
ALD: Update on the share buyback program
ALD: Update on the share buyback program
ALD: Update on the share buyback program
eqs_en 
0 14.05.20
Voltalia includes a purpose in its articles of incorporation
Voltalia includes a purpose in its articles of incorporation
Voltalia includes a purpose in its articles of incorporation
eqs_en 
0 14.05.20
DGAP-News: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
DGAP-News: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
DGAP-News: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
eqs_en 
0 14.05.20
DGAP-News: ABX464 hemmt die Replikation von SARS-CoV-2 (COVID-19) im rekonstituierten humanen Atemwegsepithelmodell
DGAP-News: ABX464 hemmt die Replikation von SARS-CoV-2 (COVID-19) im rekonstituierten humanen Atemwegsepithelmodell
DGAP-News: ABX464 hemmt die Replikation von SARS-CoV-2 (COVID-19) im rekonstituierten humanen Atemwegsepithelmodell
eqs_de 
0 14.05.20
DGAP-News: Abivax erhält Genehmigung der ANSM und der Ethikkommission zur Testung seines Entwicklungskandidaten ABX464 in einer randomisierten Phase-2b/3-Studie mit 1.034 Covid-19-Patienten
DGAP-News: Abivax erhält Genehmigung der ANSM und der Ethikkommission zur Testung seines Entwicklungskandidaten ABX464 in einer randomisierten Phase-2b/3-Studie mit 1.034 Covid-19-Patienten
DGAP-News: Abivax erhält Genehmigung der ANSM und der Ethikkommission zur Testung seines Entwicklungskandidaten ABX464 in einer randomisierten Phase-2b/3-Studie mit 1.034 Covid-19-Patienten
eqs_de 
0 14.05.20
DGAP-News: Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
DGAP-News: Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
DGAP-News: Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
eqs_en 
0 14.05.20
Kaufman & Broad SA: Dividend payment in respect of the financial year ended november 30 2019
Kaufman & Broad SA: Dividend payment in respect of the financial year ended november 30 2019
Kaufman & Broad SA: Dividend payment in respect of the financial year ended november 30 2019
eqs_en 
0 12.05.20
Kaufman & Broad SA: COMBINED ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING MAY 5, 2020
Kaufman & Broad SA: COMBINED ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING MAY 5, 2020
Kaufman & Broad SA: COMBINED ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING MAY 5, 2020
eqs_en 
0 12.05.20
Showroomprive.com:Q1 2020 net revenues: €118.2m Measured decline - sensitive rebound of activity in April
Showroomprive.com:Q1 2020 net revenues: €118.2m Measured decline - sensitive rebound of activity in April
Showroomprive.com:Q1 2020 net revenues: €118.2m Measured decline - sensitive rebound of activity in April
eqs_en 
0 07.05.20
RUBIS: A good start to the year - Fuel retail volumes up 25% - Strong demand for fuel product storage at the end of Q1
RUBIS: A good start to the year - Fuel retail volumes up 25% - Strong demand for fuel product storage at the end of Q1
RUBIS: A good start to the year - Fuel retail volumes up 25% - Strong demand for fuel product storage at the end of Q1
eqs_en 
0 06.05.20
RUBIS: Publication of 2019 Universal registration document
RUBIS: Publication of 2019 Universal registration document
RUBIS: Publication of 2019 Universal registration document
eqs_en 
0 06.05.20
ALD: Q1 2020 Trading Update
ALD: Q1 2020 Trading Update
ALD: Q1 2020 Trading Update
eqs_en 
0 06.05.20